JP2025509613A - がん治療のためのMetAP2阻害剤を含む組み合わせ - Google Patents

がん治療のためのMetAP2阻害剤を含む組み合わせ Download PDF

Info

Publication number
JP2025509613A
JP2025509613A JP2024554864A JP2024554864A JP2025509613A JP 2025509613 A JP2025509613 A JP 2025509613A JP 2024554864 A JP2024554864 A JP 2024554864A JP 2024554864 A JP2024554864 A JP 2024554864A JP 2025509613 A JP2025509613 A JP 2025509613A
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
combination
ceutically acceptable
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509613A5 (https=
Inventor
ジェイ.カーバー ブラッドリー
シャナハン ジェイムズ
コーネリウス ピーター
メイズ ベンジャミン
Original Assignee
シンデブルックス,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンデブルックス,インコーポレイティド filed Critical シンデブルックス,インコーポレイティド
Publication of JP2025509613A publication Critical patent/JP2025509613A/ja
Publication of JP2025509613A5 publication Critical patent/JP2025509613A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2024554864A 2022-03-16 2023-03-16 がん治療のためのMetAP2阻害剤を含む組み合わせ Pending JP2025509613A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263320347P 2022-03-16 2022-03-16
US63/320,347 2022-03-16
US202263340726P 2022-05-11 2022-05-11
US63/340,726 2022-05-11
PCT/US2023/064550 WO2023178255A1 (en) 2022-03-16 2023-03-16 Combinations comprising metap2 inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2025509613A true JP2025509613A (ja) 2025-04-11
JP2025509613A5 JP2025509613A5 (https=) 2026-03-26

Family

ID=85979451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554864A Pending JP2025509613A (ja) 2022-03-16 2023-03-16 がん治療のためのMetAP2阻害剤を含む組み合わせ

Country Status (9)

Country Link
US (1) US20260014194A1 (https=)
EP (1) EP4493181A1 (https=)
JP (1) JP2025509613A (https=)
KR (1) KR20240164549A (https=)
CN (1) CN119300818A (https=)
AU (1) AU2023235307A1 (https=)
CA (1) CA3245962A1 (https=)
MX (1) MX2024011197A (https=)
WO (1) WO2023178255A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102485537B1 (ko) * 2014-08-04 2023-01-05 메르크 파텐트 게엠베하 Metap-2 저해제로서의 피롤리디논 유도체
JP2022512826A (ja) * 2018-10-26 2022-02-07 シンデブルックス,インコーポレイティド MetAP2阻害剤のバイオマーカーとその応用

Also Published As

Publication number Publication date
CN119300818A (zh) 2025-01-10
US20260014194A1 (en) 2026-01-15
MX2024011197A (es) 2024-09-18
AU2023235307A1 (en) 2024-10-17
WO2023178255A9 (en) 2024-09-26
EP4493181A1 (en) 2025-01-22
WO2023178255A1 (en) 2023-09-21
KR20240164549A (ko) 2024-11-19
CA3245962A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
EP2269604B1 (en) Treatment of solid kidney tumours with a rapamycin derivative
EP4385571B1 (en) A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
TW201919615A (zh) 用於治療tnbc的化合物
JP2021505571A (ja) 末梢t細胞リンパ腫および皮膚t細胞リンパ腫を治療するための組成物および方法
JP2021169534A (ja) 化学療法の改善
WO2021180111A1 (zh) 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
US11083722B2 (en) Combination therapies for the treatment of breast cancer
JP2024542633A5 (https=)
JP2024542633A (ja) がん治療用cdk4阻害剤
JP2023501912A (ja) 急性骨髄性白血病の治療のためのdhodh阻害剤を含む組成物
JP2016520665A (ja) Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
Feng et al. Vascular disrupting effects of combretastatin A4 phosphate on murine endometriotic lesions
US11389536B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
US20260014194A1 (en) Combinations comprising metap2 inhibitors for the treatment of cancer
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
RU2847580C1 (ru) Терапевтическое средство против рака молочной железы
JP4522261B2 (ja) ブドウ膜黒色腫の処置
EP4719405A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
TW202519221A (zh) Wee1抑制劑及pkmyt1抑制劑之組合
HK40116611A (zh) 用於治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
CN119095599A (zh) 用于治疗实体肿瘤的双重选择性PI3Kδ和γ抑制剂和/或盐诱导型激酶3抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260313